<DOC>
	<DOCNO>NCT02926092</DOCNO>
	<brief_summary>The purpose study gain understand adRP progress time patient misfolded rod opsin mutation .</brief_summary>
	<brief_title>Observational Natural History Study Autosomal Dominant Retinitis Pigmentosa ( adRP )</brief_title>
	<detailed_description />
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Retinitis Pigmentosa</mesh_term>
	<criteria>1 . The subject 1 document prespecified heterozygous rhodopsin gene ( RHO ) mutation confirm genetic testing ( mutation include P23H , T17M , R135W ) . 2 . The subject least 1 eye meet 3 follow criterion : 1 . A measurable EZ area determine evaluation EZ limit sdOCT scan , horizontal EZ width great 3 mm 2 . BCVA great equal 35 letter measure Early Treatment Diabetic Retinopathy Study ( ETDRS ; equivalent 20/200 Snellen chart ) . 3 . A kinetic VF great 10 degree diameter horizontal meridian spot size III 3 . The subject ability comply clinical protocol , opinion investigator . 4 . The subject clear ocular medium adequate pupillary dilation eye permit adequate visual assessment opinion investigator . 5 . The subject agree abstain protocolprohibited medication ( ) study participation . 6 . The subject medically stable opinion investigator able fulfill protocol requirement , include ability complete assessment , without place undue burden subject/subject 's family . 7 . The subject and/or subject 's parent ( ) legally authorize guardian ( ) voluntarily sign Institutional Review Board ( IRB ) / ethic committee ( EC ) approve informed consent assent form ( ) , applicable , relevant aspect study explain discuss subject and/or subject 's parent ( ) legally authorize guardian ( ) . 8 . The subject , subject 's parent ( ) , legally authorize guardian ( ) able understand nature , scope , possible consequence study agree comply protocoldefined , schedule assessment . 1 . The subject participate interventional clinical trial participate interventional clinical trial within 90 day screen ; participation noninterventional observational study permit . 2 . The subject receive treatment treatment arm clinical trial gene therapy , stem cell therapy , retinal progenitor cell therapy , tissue transplantation , device drug delivery implantation , similar invasive therapy . 3 . The subject follow medical condition interfere consistent followup part study : 1 . Stroke 2 . Severe unstable coronary disease 3 . Endstage aggressive malignancy 4 . General poor health uncontrolled severe disease ( eg , cardiovascular , neurological , psychological , pulmonary , renal , hepatic , endocrine , gastrointestinal disorder ) opinion investigator would interfere participation study 4 . The subject follow ocular condition could interfere confound followup disease progression : Glaucoma Diabetic retinopathy Choroidal neovascularization Retinal inflammatory disease Cataract bad grade 2 ( nuclear , posterior subcapsular [ PSC ] , cortical ) High myopia ( â‰¥8 diopter ) Herpes simplex virus eye Acute infection inflammation Any ocular condition opinion investigator would interfere ability ass retinal morphology functionality 5 . The subject intraocular surgery within 90 day prior screen . 6 . The subject currently require follow protocol prohibit medication ingested medication within 30 day screen : Plaquenil Thioridazine Clofazimine Deferoxamine Phenothiazine Chlorpromazine Cisplatin Valproic acid Any drug know visual side effect 7 . The subject 3 first seconddegree family member already enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>